Christian Friedrich

5PUBLICATIONS
6CO-AUTHORS
Toxicology (incl. clinical toxicology)PharmacogenomicsPharmaceutical delivery technologiesCheminformatics and quantitative structure-activity relationships
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|Oct 29, 2025
Investigation of the Relevance of CYP3A4 Inhibition on the Pharmacokinetics of the Novel P2X3 Antagonist Filapixant: Results of In Vitro Explorations and a Fixed-Sequence Clinical Trial with Itraconazole in Healthy Volunteers.

Klaus Francke, Antje Rottmann, Stefan Klein

|May 22, 2024
Pharmacodynamics, pharmacokinetics and CYP3A4 interaction potential of the selective P2X3 receptor antagonist filapixant: A randomized multiple ascending-dose study in healthy young men.

Christian Friedrich, Dave Singh, Klaus Francke

|Dec 05, 2022
Preclinical and Clinical Pharmacokinetics and Bioavailability in Healthy Volunteers of a Novel Formulation of the Selective P2X3 Receptor Antagonist Eliapixant.

Klaus Francke, Niladri Chattopadhyay, Stefan Klein

|May 27, 2022
Safety, Pharmacodynamics, and Pharmacokinetics of P2X3 Receptor Antagonist Eliapixant (BAY 1817080) in Healthy Subjects: Double-Blind Randomized Study.

Christian Friedrich, Klaus Francke, Isabella Gashaw

|Apr 19, 2022
First-in-human study of eliapixant (BAY 1817080), a highly selective P2X3 receptor antagonist: Tolerability, safety and pharmacokinetics.

Stefan Klein, Isabella Gashaw, Sybille Baumann

Pageof 1

Frequent Collaborators

1 joint publications

Isabella Gashaw

1 joint publications

Thomas Hummel

1 joint publications

Jaclyn A Smith

1 joint publications

Alyn Morice